-
1.发明申请Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof 有权使用肌肉来源的祖细胞的软组织和骨增大和膨胀，其组合物和处理公开(公告)号：US20070065416A1
公开(公告)日：2007-03-22
申请号：US11505734
申请日：2006-08-17
CPC分类号： C12N5/0659 , A61K35/12 , A61K35/34 , C12N5/0658 , C12N2500/84 , C12N2501/70 , C12N2510/00 , C12N2533/54
摘要： The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration for dermatological conditions, gastroesophageal reflux, vesico-ureteral reflux, urinary incontinence, fecal incontinence, heart failure, and myocardial infarction.
摘要翻译： 本发明提供了肌肉衍生的祖细胞，其在移植到身体组织中后显示出长期存活，并且可以在引入（例如通过注射，移植或植入）之后增加软组织到软组织部位中。 还提供了分离肌肉来源的祖细胞的方法，以及遗传修饰细胞用于基因转移治疗的方法。 本发明进一步提供使用包含肌肉来源的祖细胞的组合物的方法，用于增加和膨胀哺乳动物，包括人类软组织，以治疗各种美容或功能状况，包括畸形，损伤，无力，疾病或功能障碍。 特别地，本发明提供了用于皮肤病学，胃食管反流，膀胱输尿管反流，尿失禁，大便失禁，心力衰竭和心肌梗死的治疗和改善。
-
2.发明申请Muscle-derived cells (MDCs) for promoting and enhancing nerve repair and regeneration 有权用于促进和增强神经修复和再生的肌源性细胞（MDC）公开(公告)号：US20050238625A1
公开(公告)日：2005-10-27
申请号：US10832542
申请日：2004-04-26
CPC分类号： C12N5/0658 , A61K35/12 , A61K35/34
摘要： The present invention describes methods involving the use of muscle derived cells (MDCs), preferably obtained from skeletal muscle, to support the innervation and repair of damaged tissues and organs, particularly associated with nerve damage or neuropathy. The invention relates to MDCs for use in methods for promoting or enhancing innervation of nerve cells, particularly in the peripheral nervous system, and their ability to contribute to the development of neuronal tissue when MDCs are introduced at or near a tissue or organ site in need of repair due to injury, damage, disease, or dysfunction. Such methods are useful for the treatment of central and peripheral nervous system disorders and to alleviate, abate, or eliminate the symptoms of neurologic or neurodegenerative diseases in animals, particularly mammals, including humans. The methods are also useful for treating both nerve and muscle tissue following injury, damage, or dysfunction to these tissue types.
摘要翻译： 本发明描述了使用优选从骨骼肌获得的肌肉衍生细胞（MDC）来支持损伤的组织和器官的神经支配和修复，特别是与神经损伤或神经病有关的方法。 本发明涉及用于促进或增强神经细胞神经细胞，特别是周围神经系统神经支配的方法中使用的MDC，以及当将MDCs引入到需要的组织或器官部位处或附近时有助于神经元组织发育的能力 由于受伤，损伤，疾病或功能障碍引起的修复。 这样的方法可用于治疗中枢和周围神经系统疾病并减轻，减轻或消除动物，特别是包括人在内的哺乳动物的神经退行性疾病或神经变性疾病的症状。 这些方法对于在损伤，损伤或这些组织类型的功能障碍之后治疗神经和肌肉组织也是有用的。
-
3.发明授权Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof 有权使用肌肉来源的祖细胞的软组织和骨增大和膨胀，其组合物和处理公开(公告)号：US08986671B2
公开(公告)日：2015-03-24
申请号：US11505734
申请日：2006-08-17
CPC分类号： C12N5/0659 , A61K35/12 , A61K35/34 , C12N5/0658 , C12N2500/84 , C12N2501/70 , C12N2510/00 , C12N2533/54
摘要： The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration for dermatological conditions, gastroesophageal reflux, vesico-ureteral reflux, urinary incontinence, fecal incontinence, heart failure, and myocardial infarction.
摘要翻译： 本发明提供了肌肉衍生的祖细胞，其在移植到身体组织中后显示出长期存活，并且可以在引入（例如通过注射，移植或植入）之后增加软组织到软组织部位中。 还提供了分离肌肉来源的祖细胞的方法，以及遗传修饰细胞用于基因转移治疗的方法。 本发明进一步提供使用包含肌肉来源的祖细胞的组合物的方法，用于增加和膨胀哺乳动物，包括人类软组织，以治疗各种美容或功能状况，包括畸形，损伤，无力，疾病或功能障碍。 特别地，本发明提供了用于皮肤病学，胃食管反流，膀胱输尿管反流，尿失禁，大便失禁，心力衰竭和心肌梗塞的治疗和改善。
-
4.发明授权Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof 有权使用肌肉来源的祖细胞的软组织和骨增大和膨胀，其组合物和处理公开(公告)号：US08685385B2
公开(公告)日：2014-04-01
申请号：US13038827
申请日：2011-03-02
IPC分类号： A61K35/34
CPC分类号： C12N5/0659 , A61K35/12 , A61K35/34 , C12N5/0658 , C12N2500/84 , C12N2501/70 , C12N2510/00 , C12N2533/54
摘要： The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration for dermatological conditions, gastroesophageal reflux, vesico-ureteral reflux, urinary incontinence, fecal incontinence, heart failure, and myocardial infarction.
摘要翻译： 本发明提供了肌肉衍生的祖细胞，其在移植到身体组织中后显示出长期存活，并且可以在引入（例如通过注射，移植或植入）之后增加软组织到软组织部位中。 还提供了分离肌肉来源的祖细胞的方法，以及遗传修饰细胞用于基因转移治疗的方法。 本发明进一步提供使用包含肌肉来源的祖细胞的组合物的方法，用于增加和膨胀哺乳动物，包括人类软组织，以治疗各种美容或功能状况，包括畸形，损伤，无力，疾病或功能障碍。 特别地，本发明提供了用于皮肤病学，胃食管反流，膀胱输尿管反流，尿失禁，大便失禁，心力衰竭和心肌梗死的治疗和改善。
-
5.发明申请BONE AUGMENTATION UTILIZING MUSCLE-DERIVED PROGENITOR COMPOSITIONS IN BIOCOMPATIBLE MATRIX, AND TREATMENTS THEREOF 有权使用生物化学基质中的肌肉衍生的原料组合物的骨质保护及其治疗公开(公告)号：US20100215623A1
公开(公告)日：2010-08-26
申请号：US12543311
申请日：2009-08-18
申请人： Arvydas Usas , Karin Payne , Thomas Payne , Ronald Jankowski , Johnny Huard
发明人： Arvydas Usas , Karin Payne , Thomas Payne , Ronald Jankowski , Johnny Huard
CPC分类号： A61L27/3895 , A61K35/12 , A61K35/38 , A61L27/3629 , A61L27/365 , A61L27/3847 , A61L27/54 , A61L27/58 , A61L2300/64 , A61L2430/02 , A61L2430/40 , C12N5/0659 , C12N11/02 , C12N2533/92
摘要： The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment non-soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of non-soft tissue (e.g. bone) when combined with a biocompatible matrix, preferably SIS. The invention further provides methods of using compositions comprising muscle-derived progenitor cells with a biocompatible matrix for the augmentation and bulking of mammalian, including human, bone tissues in the treatment of various functional conditions, including osteoporosis, Paget's Disease, osteogenesis imperfecta, bone fracture, osteomalacia, decrease in bone trabecular strength, decrease in bone cortical strength and decrease in bone density with old age.
摘要翻译： 本发明提供肌肉衍生的祖细胞，其在移植到身体组织中后显示出长期存活，并且可以在引入（例如经由注射，移植或植入）之后增加非软组织到非软组织部位（例如， 骨）与生物相容性基质（优选SIS）组合时。 本发明还提供了使用包含肌源性祖细胞的组合物与生物相容性基质的方法，用于在治疗各种功能状况（包括骨质疏松症，佩吉特氏病，成骨不全，骨折）中增加和膨胀哺乳动物，包括人类骨组织 ，骨软化，骨小梁强度降低，骨皮质强度下降，老年骨密度降低。
-
公开(公告)号：US20070264239A1
公开(公告)日：2007-11-15
申请号：US11746979
申请日：2007-05-10
申请人： Johnny Huard , Bruno Peault
发明人： Johnny Huard , Bruno Peault
IPC分类号： C12N5/08
CPC分类号： C12N5/0691 , C12N5/0657 , C12N5/0658 , C12N2506/1384 , C12N2506/28
摘要： In one embodiment, the invention provides a pericyte having a marker pattern comprising CD146+, CD34−, and CD45−, wherein said pericyte is substantially isolated from cells that are CD146− or CD31+ or CD34+ or CD45+ or CD56+ or NG2− or CD133−. The invention also provides populations of such pericytes. In another embodiment, the invention provides a method for isolating a pericyte. In another embodiment, the invention provides a method for modeling tissue in vivo.
摘要翻译： 在一个实施方案中，本发明提供了具有包含CD146 +，CD34-和CD45-的标记图案的周细胞，其中所述周细胞基本上与CD146-或CD31 +或CD34 +或CD45 +或CD56 +或NG2-或CD133-的细胞分离。 本发明还提供了这种周细胞的种群。 在另一个实施方案中，本发明提供了一种隔离周细胞的方法。 在另一个实施方案中，本发明提供了一种用于在体内建模组织的方法。
-
7.发明申请Muscle-derived cells (MDCs) for treating muscle- or bone-related injury or dysfunction 有权肌肉来源的细胞（MDCs）用于治疗肌肉或骨骼相关的损伤或功能障碍公开(公告)号：US20050265978A1
公开(公告)日：2005-12-01
申请号：US11040900
申请日：2005-01-21
申请人： Michael Chancellor , Johnny Huard
发明人： Michael Chancellor , Johnny Huard
IPC分类号： A01N43/04 , A01N63/00 , A61K45/00 , A61K48/00 , C12N5/077 , C12N15/09 , C12N15/63 , C12N5/08
CPC分类号： A61K35/34 , C12N5/0658 , C12N5/0659 , C12N2501/105 , C12N2501/113 , C12N2501/115 , C12N2501/13 , C12N2510/00 , C12N2510/04
摘要： The present invention provides muscle-derived cells, preferably myoblasts and muscle-derived stem cells, genetically engineered to contain and express one or more heterologous genes or functional segments of such genes, for delivery of the encoded gene products at or near sites of musculoskeletal, bone, ligament, meniscus, cartilage or genitourinary disease, injury, defect, or dysfunction. Ex vivo myoblast mediated gene delivery of human inducible nitric oxide synthase, and the resulting production of nitric oxide at and around the site of injury, are particularly provided by the invention as a treatment for lower genitourinary tract dysfunctions. Ex vivo gene transfer for the musculoskeletal system includes genes encoding acidic fibroblast growth factor, basic fibroblast growth factor, epidermal growth factor, insulin-like growth factor, platelet derived growth factor, transforming growth factor-β, transforming growth factor-α, nerve growth factor and interleukin-1 receptor antagonist protein (IRAP), bone morphogenetic protein (BMPs), cartilage derived morphogenetic protein (CDMPs), vascular endothelial growth factor (VEGF), and sonic hedgehog proteins.
摘要翻译： 本发明提供肌肉衍生的细胞，优选成肌细胞和来自肌肉的干细胞，其被遗传工程化以含有和表达这种基因的一个或多个异源基因或功能区段，用于在肌肉骨骼的位点或附近递送编码的基因产物， 骨，韧带，半月板，软骨或泌尿生殖系疾病，损伤，缺陷或功能障碍。 本发明特别提供离体成肌细胞介导的人诱导型一氧化氮合酶的基因递送以及所产生的损伤部位周围及其周围的一氧化氮，作为降低泌尿生殖道功能障碍的治疗。 肌肉骨骼系统的离体基因转移包括编码酸性成纤维细胞生长因子，碱性成纤维细胞生长因子，表皮生长因子，胰岛素样生长因子，血小板衍生生长因子，转化生长因子-β，转化生长因子-α，神经生长的基因 因子和白细胞介素-1受体拮抗蛋白（IRAP），骨形态发生蛋白（BMPs），软骨来源的形态发生蛋白（CDMPs），血管内皮生长因子（VEGF）和声音刺猬蛋白。
-
8.发明授权Bone augmentation utilizing muscle-derived progenitor compositions in biocompatible matrix, and treatments thereof 有权使用生物相容性基质中的肌源性祖细胞组合物进行骨增生及其治疗公开(公告)号：US09199003B2
公开(公告)日：2015-12-01
申请号：US12543311
申请日：2009-08-18
申请人： Arvydas Usas , Karin Payne , Thomas Payne , Ronald Jankowski , Johnny Huard
发明人： Arvydas Usas , Karin Payne , Thomas Payne , Ronald Jankowski , Johnny Huard
IPC分类号： A61L27/38 , A61K35/38 , C12N5/077 , A61L27/36 , A61L27/54 , A61L27/58 , C12N11/02 , A61K35/12
CPC分类号： A61L27/3895 , A61K35/12 , A61K35/38 , A61L27/3629 , A61L27/365 , A61L27/3847 , A61L27/54 , A61L27/58 , A61L2300/64 , A61L2430/02 , A61L2430/40 , C12N5/0659 , C12N11/02 , C12N2533/92
摘要： The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment non-soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of non-soft tissue (e.g. bone) when combined with a biocompatible matrix, preferably SIS. The invention further provides methods of using compositions comprising muscle-derived progenitor cells with a biocompatible matrix for the augmentation and bulking of mammalian, including human, bone tissues in the treatment of various functional conditions, including osteoporosis, Paget's Disease, osteogenesis imperfecta, bone fracture, osteomalacia, decrease in bone trabecular strength, decrease in bone cortical strength and decrease in bone density with old age.
摘要翻译： 本发明提供肌肉衍生的祖细胞，其在移植到身体组织中后显示出长期存活，并且可以在引入（例如经由注射，移植或植入）之后增加非软组织到非软组织部位（例如， 骨）与生物相容性基质（优选SIS）组合时。 本发明还提供了使用包含肌源性祖细胞的组合物与生物相容性基质的方法，用于在治疗各种功能状况（包括骨质疏松症，佩吉特氏病，成骨不全，骨折）中增加和膨胀哺乳动物，包括人类骨组织 ，骨软化，骨小梁强度降低，骨皮质强度下降，老年骨密度降低。
-
9.发明授权Rapid preparation of stem cell matrices for use in tissue and organ treatment and repair 有权用于组织和器官治疗和修复的干细胞基质的快速制备公开(公告)号：US08790680B2
公开(公告)日：2014-07-29
申请号：US13046120
申请日：2011-03-11
CPC分类号： A61L27/3834 , A61K35/12 , A61L27/225 , A61L27/3629 , A61L27/3679 , A61L2430/22 , C12N5/0068 , C12N5/0658 , C12N5/0668 , C12N5/0697 , C12N2533/56 , C12N2533/74 , C12N2533/90 , C12N2533/92
摘要： A rapid method for preparing stem cell and physiologically acceptable matrix compositions for use in tissue and organ repair is described. Compared with previous tissue engineering materials, the stem cell-matrix compositions of the present invention do not require long-term incubation or cultivation in vitro prior to use in in vivo applications. The stem cells can be from numerous sources and may be homogeneous, heterogeneous, autologous, and/or allogeneic in the matrix material. The stem cell-matrix compositions provide point of service utility for the practitioner, wherein the stem cells and matrix can be combined not long before use, thereby alleviating costly and lengthy manufacturing procedures. In addition, the stem cells offer unique structural properties to the matrix composition which improves outcome and healing after use. Use of stem cells obtained from muscle affords contractility to the matrix composition.
摘要翻译： 描述了用于制备用于组织和器官修复的干细胞和生理上可接受的基质组合物的快速方法。 与以前的组织工程材料相比，本发明的干细胞 - 基质组合物在用于体内应用之前不需要在体外长期孵育或培养。 干细胞可以来自多种来源，并且在基质材料中可以是均质的，异质的，自体的和/或同种异体的。 干细胞 - 基质组合物为实践者提供了服务点，其中干细胞和基质在使用前可以组合不久，从而减轻昂贵且冗长的制造过程。 此外，干细胞为基质组合物提供独特的结构特性，可改善使用后的结果和愈合。 使用从肌肉获得的干细胞可提供收缩性的基质组成。
-
公开(公告)号：US08741277B2
公开(公告)日：2014-06-03
申请号：US11505735
申请日：2006-08-17
IPC分类号： A61K35/34
CPC分类号： C12N5/0659 , A61K35/12 , A61K35/34 , C12N5/0658 , C12N2500/84 , C12N2501/70 , C12N2510/00 , C12N2533/54
摘要： The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration for dermatological conditions, gastroesophageal reflux, vesico-ureteral reflux, urinary incontinence, fecal incontinence, heart failure, and myocardial infarction.
-
-
-
-
-
-
-
-
-
搜索结果
27 条记录 (耗时 0.025 秒)
